Graminex社の”花粉エキスG63”による前立腺炎への知見

食事編_表1_4_0508

Microsoft Word - 表紙資料２－４

(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

取扱説明書

ED-601 ED-501 ED-401 2 3 4 23 14 5 6 18 10 7 1 2 6 3 4 8 9 16 16 16 12 1 2 18 10 2 1 5 12 11 1 2 1 2 12 1 2 13 16 14 3 2 4 1 1 2 16 3 4 18 15 1 2 16 2 3 1 1 2 3 18 17 18 22 19 D A C 20 A B 22 B C D 22

喘息について\(公健協会宛02-5作成\)

Q & A Q & A 1.? 20 2. 1) 2) 3) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 8) 9) 3. NHK ( ) 4 10 1 200mg ( ) ( 1 ) 4. ( ) ( ) 5. ( ) ( ) 6. β 2 ( ) 7. ( ) 1 8. 1. 2. 3. 4. 5. 6. 7. 8. 9. 2 5 7 1. 1 10 1) 2) 3) 30

グラミネックス社の花粉エキス

, Pollen Aid TM Graminex L.L.C. 95 Midland Road, Saginaw, MI 48603 U.S.A. www.graminex. com 2000 1 40 4 300 3 ISO 9001, Q9001-2000, ng.m.p. 1 G60 GFX( ) 20:1 G63 1980 22 27 100 G60 GFX G63(G60 GFX ) 2

02

Q A Ax Pb Ni Cd Hg Al Q A Q A Q A 1 2 3 2 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 8 0 0 1 2 3 4 1 0 1 2 Q A ng/ml 4500 D H E A 4000 3500 3000 2500 2000 DHEA-S - S 1500 1000 500 0 10 15 20 25 30 35 40 45

0.02ml IgE RAST MAST CAP 2

( ) 1 0.02ml IgE RAST MAST CAP 2 3 1963 30 4 1986 20 39 IgE 30% 1988 54.7% IgE 47.6% 1990 892 IgE 27% 12% 1995 2379 1995 8 15 1996 1 12 2335 98.5% 2335 24 61 47 44.0 1 1) 2335 613 26.3% 2 5 613 43.4 44.2

14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0

第３章 焼却灰溶融システムの現状、焼却灰溶融スラグのリサイクルの動向・問題点

18 5 23 450 100~150 1300 1998 10 25 1 1 27 1819 60 3 300t 28.8t 2 62 118t16 12.3 16h 24 3 4 120t 9.6t24h 3 4 100t24h 15t24h 3 4 600t24h 500t24h 5 2 300t24h 75t24h 6 8 80 24h 9.6 24h 4 300t24h 52 24 11

A5_Catalog-US-JN_ indd

66 22 g 13 g 8 g 5 g 7500 IU 150% 300 mg 600 IU 100 IU 80 mcg 3 mg 3.5 mg 40 mg 4 mg 500 mcg 12 mcg 300 mcg 20 mg 1000 mg 150 mcg 400 mg 15 mg 105 mcg 2 mg 2 mg 180 mcg 125 mcg 15 mg 3.6 g ** 3.8 g **

レイアウト 1

1 3 6 7 8 3 6 7 8 g mg 6 1 16 16 18 16 13 138 13 16 1 11 8 78 8 17 9 9 g mg 18 13 1 1 1 99 6 3 36 3 3 8 1 18 18 18 16 16 1 1 g mg 1 1 13 13 1 11 11 g mg 8 6 g 1 g mg 93 38 9 93 8 8 176 1 1 1 1 11 18

Imamura, 200827-30 4-8 20 C Imamura, 2008 TRPM8 Chen, 2009; Zhang, 2012Chen, 2009 Noguchi, 2013) Yamagishi, 2013 1 TRPM8 C Imamura, 2013 Zhang,2006; Imamura, 2008 ATP Imamura, 2009 C C Imamura, 2013 BNP

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 JAS 1-2 1-2 112 13 1-11-13 100870mg 100830mg11000 1100020.002 2 50 100 2 100 500 2 100 109252165 4514782 7 2.0kg 2-19220.05kg0.2kg

.H...A.....M.[00.\...\01.^.O.Z

EL-G37

EL-G37 A A A A A A A A A A A A A A GT F543210A CE CA 4 00. 00 23.80 2 015.6250 77.14286 96. 91. 102. 25. 9. 1 700. 2 720. 2.5 7. 20. 25. 220. 400. 4 096. 4.685 0.084 M 125. M 28. M 85.

12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36

untitled

~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/

橡アロマセラピー症状別処方例.PDF

1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20

CW3_AX056A01.indd

165 166 167 168 169 170 A 171 172 173 174 175 176 177 178 179 ritalin http://www.ncnp.go.jp/nimh/yakubutsu/drug-top/data/ researchjhs.pdf 180 mg mg http://www.novartis.co.jp/product/rit/te/te_rit. html

1 2 3 4 5 68g 9g 2g 0.2mg 0.8mg 316kcal 316cal 326kcal 326cal 6 010 3035 15 5355 30 120 20 7 8 9 10 11 () () () 12 1 3 1 5 1 80kcal 20 30 20 30 1 9 7.5 13 7.58.5 910.5 1213.5 11.512.5 14 15 79 23 1520

001-007　扉・口絵・目次

1 6 6 7 1 a a a a 2 a a a 3 4 5 a 6 7 8 9 10 a 11 a a a 12 13 14 15 a 16 17 18 19 20 21 22 23 24 b b 25 b 26 27 aa 28 r r 29 a s d f 30 b b 31 32 33 1 34 35 36 37 38 6 39 6 40 41 42 43 44 45 7 47 48

w

22

2015 75 7074 6569 2064 26470 21 22 4,060 1,330 23 24 15,000 80 24,600 15,000 15,000 24,600 15,000 24,600 15,000 24,600 37,200 145 520 383 44,400 25 26 280 160280 280 346 160 80 160 37,200 24,600 15,000

2015taisetumatome.rtf

B B B( ) B3 - B3 1 3g 1/3 B 1. B1() B1() 2. B2() B2() 3. B5() B5() 4. B6() B6()( ) 5. B12() B12() 6. 1q60 160m 50m 50m 20m 8520 80 10 64 5075 30 80 B B 1 30 BB BC EPA . ?? 6 C E C 1 30 1 0.4mg4

partial androgen deficiency in agingmalepadam lateonset hypogonadism LOH ED 3 Aging Males Symptoms scale AMS androgen androgen androgen androgen Morley JE 17 52.3 20 48.5 STAI SDS STAI TEG N A C 40 2 2

2011 2011 2011 100/m 0.003/ 0.0005 / 0.01/ 0.01 / 0.01/ 0.05 / 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005

I

I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4

サプリメント4.PDF

Vol.13,No,2004 106 Oct.200Vol.13 No. ACE 1000 10mmHg ACE ACE ACE Vol.13,No.4,2004 107 L- L- EPA DHA B 2002 a. CSPHP A D E K b. TG DAG DA EPA/DHA EPA DHA n-3 n- EPA DHA n- EPA DHA Vol.13,No,2004 108 n-6

CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM CD-ROM 4000 ED COOLSCAN IV ED 4000 ED 4000 ED 4000 ED 4000 ED 4000 ED 4000 ED 4000

22“ƒ†Q’ÓŠ¹

1 122 23 122 23 10 2 20 20 10 22 18 122 23 10 10 3 1 3 3 2 3 4 2 (e-tax) 4 1 15 1 2 3 4 6 23 122 2 3 122 23 4 4 23 122 660-8544 (06) 64161381 5 122 23 6 23 122 1400370 7 122 9 MonotaRO 23 [] ENEOS 11 30

1 3 3 5 6 9 10 12 13 14 15 17 18 18 19 20 22 24 25 28 28 29 30 31 31 32 32 33 33 2 34 35 35 36 36 36 39 40 41 41 42 43 43 44 44 45 48 50 50 51 51 51 52 53 55 57 59 61 63 65 67 69 71 73 75 77 3 82 84 86

経済論集　４６‐１（よこ）（Ｐ）／２．三崎

1 1 14 2 1866 8 20 20 2 4 1871 20 3 4 2 1969 9 12 28 33 3 1970 35 5 1965 p.119. 1995 p.67 1960 p.86. 1965 p.120. 1927 p.5. 1942 p.127, p.129. 10 1877 7 12 16 6 10 7 10 1877 8 7 6 8 16 25 29 10 1877 9 1

() (1) (2) (1) 235 () 251 (1) 1,745 1,737 (2) 1,597

16 4 15 1 51 1 10 19912 1618 15[ ] 49,50016121 1612 15[ ] 16 1515 16 15[ ] 1111 12 1613 16 4 15 2 11 199 1618 1511 1512241612 () (1) (2) (1) 235 () 251 (1) 1,745 1,737 (2) 1,597 16 4 15 3 363 (1) 203,600201,450

untitled

28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS

肝臓病教室201207v2配布用.pptx

24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0

pdf

RP. 1 15 5 0.5g/ 1 1 1 2 1 2 28 5mg/ 1 1 1 3 20 105 S-1 4 2 2 3 3 day15 15 S-115 S-1 S-1 0.12 0.22 0.12 106 2 107 3 65S-13day15 S-1 S-1 108 109 1 1 S-1 33-1 S-1 110 S-1 3day15 1 4 2 116 -1 5 1-2 2-3 day3

FXneo FXneo PC FXneo FX 1 2

FXneo FXneo PC FXneo FX 1 2 FXneo 1. 04 2. 07 PC FX 07 08 09 10 11 13 3. 14 14 19 4. 20 5. 21 3 FXneo 1. 1 4 FXneo 1. 1 1 / 1 5 FXneo 1. 1 2 6 FXneo 2. PC PC FXneo- 2 [ ] 7 FXneo 2. PC 8 FXneo 2. PC 50pips

馬のライフステージ別栄養管理　Ⅰ　～繁殖牝馬～

平成25年度調理師試験問題

25 15 60 HB 2 1 1 2 36 1961 46 1971 56 1981 3 1991 3 4-1 - 5 6 7 8 6 2 12 31 1 15 1 15 4 15 4 15-2 - 9-3 - 10 11 12 13 3-4 - 14 腿 15 16 WHO 22 2010 17 18 1-5 - 19 1 g 4 kcal 4 kcal 9 kcal 9 kcal 20 21

untitled

...1... 3 1... 3 2... 4 3... 4 4... 5...... 6 1... 6 2... 7 3... 8 4... 9 5... 10... 12 1... 12 2... 13 3... 14 4... 16...... 19 1... 19 2... 20 3... 22 4... 24...... 25... 26 1... 26 2... 26 3... 26......

ml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G

No.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h htmL)

Drug Information News No.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h0925-1.htmL) 2 No.192 HP DI [ ] 1. -1a - 50 100 300 2. 7501500 3000750 1500 3000 60009000 12000240006000 9000 12000 24000

1 2

1 2 1 1pH WPC-Type25WPH-Type25F-Type N-Type 3 21997a 2 1997b 31997b 4 41 32008 42008 12008 42 5 4Uchino et al., 2003 51 2 3 12 4 8 16 5 6 LDH IgE Uchino et al., 2003 LDH 1 24 1 5120 39 52AD 5 AD NC/Nga

‚å™J‚å−w“LŁñfi~P01†`08

156 2003 2 3 4 5 6 7 8 9 c f c a g 10 d c d 11 e a d 12 a g e 13 d fg f 14 g e 15 16 17 18 19 20 21 db de de fg fg g gf b eb g a a e e cf b db 22 d b e ag dc dc ed gf cb f f e b d ef 23 f fb ed e g gf

9 10 21 4 23 3 24 11 2012 24 5 28 4

9 10 21 4 23 3 24 11 2012 24 5 28 4 1 2 3 4 5 6 7 8 9 1 2 3 4 10 11 12 13 14 15 16 SIDS 17 18 19 20 21 22 1 2 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 1 2 3 4 5 6 01 3 4 P1 P P 10 11

2

VL-MG10 6 2 3 102 4 5 VL-MG10 6 50 128 '" 128 6 å å å AAAAA AAAAAAA AAAAAAAAA»»» »»»»» 7 »»»»»»» 8 »»»»»» 9 »» ±»»» ± 10 »»»»» 11 »»»»»»»» 12 »»»»»»»»»» 13 »»»»»»»»»»»»»»»»»»»»»» 14 »»»»»»»»»»» 15 1 38

近畿中国四国農業研究センター研究報告　第７号

230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15

, ,279 w

No.482 DEC. 200315 14 1754,406 100.0 2160,279 w 100 90 80 70 60 50 40 30 20 10 28.9 23.8 25.0 19.3 30.4 25.0 29.5 80.7 75.0 75.0 70.5 71.1 69.6 76.2 7 8 9 10 11 12 13 23.2 76.8 14 14 1751,189 100.0 2156,574

国試過去問集.PDF

I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III

商学５７‐５／１．山村

217 1982 1998 2002 14 7 7 250 3 2 2004 16 2004 a 90 218 1 1 1948 23 25 19 2004 47 3 13 2 14 1969 2 25 25 20 21.1 70 34.5 40 219 50 25 2004 1kg1 l 1,000 mg1 g 250 mg 1mg 1mg 1 mg 19 1911 44 2005 25 50 1498

200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,

NG 3 1 MDI 製 剤,DPI 製 剤 違 い MDI DPI 表 1MDIDPI 表 2 58

1 第 1 NG 2 57 NG 3 1 MDI 製 剤,DPI 製 剤 違 い MDI DPI 表 1MDIDPI 表 2 58 2 使 用 可 能 な 吸 入 ステロイドと 投 与 量 目 安 MDI DPI g g g 100200 400 800 第 DPI 100200 400 800 DPI 200400 0.5mg 800 1.0mg 1600 2.0mg 100200 400 800

2014 6 115 123 総 説 I -VG, 2014 7 24 2014 8 15 -VG, -VG 115

2014 6 107 114 総 説 2014 7 25 2014 8 1 2014 1 20 OTC 107 2014 6 115 123 総 説 I -VG, 2014 7 24 2014 8 15 -VG, -VG 115 2014 6 124 132 原 著 1, 2, 3 4, 5 6 7 8 9 10 3 11 12 1 2 3 4 5 6 7 8 9 10 11 12 2014 3 24

-1-19 753-0214 TEL 083-927-7031083-927-7029 FAX 083-927-0214 e-mail a17201@pref.yamaguchi.lg.jp - 2 - -3-. 20kg 60% 2kg 2 3 -4-30 3 15 3-0.05 0.4 NaOH 0.5 20 -5-. 1 1,757g 69% 30 -6- -7- -8- C C H17 18

香南市・香美市のニラ

ROTTLER Chinese chives Alliaceae Allium 133 33 33 33 133 41 36 12 1 ha2 3 JA 4 1 H17 23 2010 4 JA 22 40,000~50,000 10a 4 100 5 120 6~8 120~150 20,000~30,000 10a 810 30 911 47 40 123 50 10a kg 4,000kg

1 8 7 30 8 15 12 11 30 12 15 18 18 00 18 30 10 15 19 30 9 45 13 45 11 30 18 9 15 30 30 1 1 2

7 19 20 30 1 1 8 7 30 8 15 12 11 30 12 15 18 18 00 18 30 10 15 19 30 9 45 13 45 11 30 18 9 15 30 30 1 1 2 3 10 11 12 13 4 6 6 14 15 16 17 18 5 1 1 6 2 7 () 8 9 10 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - -

BMI BMI

() () 2 QOL () () QOL 11 6 14 20 13.9 20 BMI 12 70 40 11 6 14 20 13.9 20 BMI 12 70 40 57.1 100 ) 1 100 1 250 11 11 430 315 73.3 494 247 50.0 322 60 18.6 12 70 62 88.6 100 18 57.1 1 100 1 250 430 315 73.3

1 X X T T X (topology) T X (open set) (X, T ) (topological space) ( ) T1 T, X T T2 T T T3 T T ( ) ( ) T1 X T2 T3 1 X T = {, X} X (X, T ) indiscrete sp

1 X X T T X (topology) T X (open set) (X, T ) (topological space) ( ) T1 T, X T T2 T T T3 T T ( ) ( ) T1 X T2 T3 1 X T = {, X} X (X, T ) indiscrete space T1 T2 =, X = X, X X = X T3 =, X =, X X = X 2 X

untitled

2 prologue Magnesia Alba 3 #01 about Magnesium 4 #01 about Magnesium 6 7 #02 in the Athletes Life 8 9 #02 in the Athletes Life 10 11 #02 in the Athletes Life 12 13 Athlete's Life Magnesium #03 Q A 14

untitled

prologue Magnesia Alba 2 3 4 about Magnesium #01 #01 about Magnesium 6 7 #02 in the Athletes Life 8 9 #02 in the Athletes Life 10 11 12 13 in the Athletes Life #02 14 15 #03 Athlete's Life Magnesium Q

07.11’ì’¼-Ł\”ƒ.Ł\4

TOWN NEWS 2007 Nov11 15 CONTENTS 11 1218 1922 2 18 18 17 10920800 712895 29858745 141207609 089817 33427556 433257 358 12 6480 333 11 75285 82 9060 39 37412 33 1802 31 8908 27 95762 22 78607 75 64388 3

FMV-BIBLOシリーズ（2008年4月版）製品カタログ（後編）

SOFTWARE 2007 2007 2007 21 NF NX MG LOOX R LOOX U 22 23 NF NX MG LOOX R LOOX U 24 TM 25 http://jp.fujitsu.com/about /csr/eco/ NF NX MG LOOX R LOOX U 26 New 27 NF NX MG LOOX R LOOX U 28 P.19 P.08 P.08 P.18

231 331 812 230 350 500 100 30 50 100 150 580291954 500100 50175 500 15700 80 200 391964 224 1990 521977 1997 232 51 391964 225 25 26 27 28 29 30 233 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 234 46

L- 19 L L- L-

0131001 15 1 31 49 35 145 14 5 19 4 23 15 3 10 7 15 634 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 L- 19 L- 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49

untitled

- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -

応用数学特論.dvi

1 1 1.1.1 ( ). P,Q,R,.... 2+3=5 2 1.1.2 ( ). P T (true) F (false) T F P P T P. T 2 F 1.1.3 ( ). 2 P Q P Q P Q P Q P or Q P Q P Q P Q T T T T F T F T T F F F. P = 5 4 Q = 3 2 P Q = 5 4 3 2 P F Q T P Q T

Y z x c n m, 0 3 4 5

Y z x c n m, 0 3 4 5 5 K K K 5 7 65 65 Y Y o o 56 65 7 s s s s s @ x v z c \ b z x c \ c e 0 d b f d 65 C C D E F B E k 7 k 778 23 k 850 778 0 C C F F C 5 F F ^ C B E B F F O O P 5 5 Z D D D D B F C F

P3 P6 P7 P8 P9 P12 P13 P16 P17 P18 P19 P20 P21 P24 P25 P26 P27 P28 P29 P30 P31 P33 P35 P36 P37 P38 1 2

PRICE LIST vol.8 P3 P6 P7 P8 P9 P12 P13 P16 P17 P18 P19 P20 P21 P24 P25 P26 P27 P28 P29 P30 P31 P33 P35 P36 P37 P38 1 2 150,000 70,000 80,000 130,000 100,000 150,000 5,000 2,000 3,000 40,000 5,000 30,000

LOH症候群(加齢性腺機能低下症)のマネジメント

LOH 症候群のマネジメント 分野 : 内分泌 テーマ : 診断検査 作成者 : 岡山大学病院総合内科 監修者 : 岡山大学病院総合内科 原田洸 大塚文男 LOH 症候群 (late-onset hypogonadism) とは 加齢男性性機能低下症候群 男性更年期障害とも呼ばれる 加齢に伴う血中男性ホルモンの低下に基づく症候群 性機能障害 抑うつ状態 筋力低下 骨粗鬆症 貧血 認知機能低下 メタボリック症候群

1) 1) 1 R 2 3 4 5 6 3) 4) 5) Punch 7 10g/mL(63.6mol/L) 20mg/kg 78 5 23 Cmax 250mg 3.9g/ml 500mg 6.0g/ml1000mg 8g/ml2000mg 15g/ml 33.4 110-116mL/min 1,8) 8 95 9 10 ( ) 11 desa 12 13 12) 2.5 5 19 Rec assayames

[ml] 180 160 140 120 100 80 60 40 20 0 Cumulative biogas production [ml/mg-input VS] 0 10 20 30 40 50 60 [] 1 0.8 0.6 0.4 0.2 0 dog food PLA foam 0 10 20 30 40 50 days RUN1-1 RUN1-2 RUN2-1 RUN2-2 RUN3-1

report.indd

*: p

1総説_諸疾患における亜鉛測定の意義.indd

O 43,000 C 16,000 H 7,000 N 1,700 Ca 1,160 P 670 K 150 S 112 Cl 85 Na 63 Mg 25 70 100 3 5mg 15 mg 0.5 0.1 mg 0.1 3.0 mg 0.5 1.0 mg 1.0 5.0 mg -P B 12 0.01 0.06 mg 0.02 0.2 mg 0.01 0.04 mg 0.02 0.2 mg 0.1

ニトロトルエン

4-115 116 4-3 2 117 4- g/kg/day mg/kg/day 25 125 30 40 50 100 250 300 ( ) ( ) ( ) ( ) F1 42 10 118 ER 10-11 M 1% 10-11 10-4 M ER 10-4 M 3% 10-11 10-4 M E-screen 10-9 10-4 M AR ( ) 10-6 10-4 M AR ( ) 10-6

1 1 ー (LPG ) (LPG ) LNG ( ( ) () LPG LNG LPG LNG 2 10^6 kwh () TJ () TJ () TJ (LPG) TJ TJ m 3 1990(H2)2005 1990 LPG L/

- 108 -

3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg

Taro10-mizushima01.PDF

- 1 - ATAGO N- % % g % g % g % g % g % g Brix% g g ml ml mgm / l ml mg mol/l mol/l mol/l ph NaSO mol/ l ml / g mg mg ml mol/l ml ml L- L- FIBE-MINI FIBE-MINI % % FIBE-MINI % g % g % g % C mg mg mg

コンタクトセンター全体の品質向上を目指すには？ ～品質を考える上での体系とケーススタディ～?

INFO-WORKSINC.ALLRIGHTSRESERVED. INFO-WORKSINC.ALLRIGHTSRESERVED. A. B. C. 13 D. E. INFO-WORKSINC.ALLRIGHTSRESERVED. A. COPYRIGHT2009 INFO-WORKSINC.ALLRIGHTSRESERVED. B.? EX. COPYRIGHT2009 INFO-WORKSINC.ALLRIGHTSRESERVED.

ティムコ様

Think in the field Think in the field. Fishing tackle Fly-Fishing Quiet sports Lure-Fishing Ecology Outdoor clothing Outdoor products 1 2 IgE Special Column 4 3 Special Column T O P I C S 5 6 7 8 10 9

62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -

1 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] g/dl A 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - [ ] Point ~ 62 [ ] [ ] [ ] [ ] [ ] [ ] / /

function2.pdf

2... 1 2009, http://c-faculty.chuo-u.ac.jp/ nishioka/ 2 11 38 : 5) i) [], : 84 85 86 87 88 89 1000 ) 13 22 33 56 92 147 140 120 100 80 60 40 20 1 2 3 4 5 7.1 7 7.1 1. *1 e = 2.7182 ) fx) e x, x R : 7.1)

% %

4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5

untitled

BALL BUSH UNIT SN-A SN-10A SNF-A SNF-10A Copyright 011 ASK Limited all rights reserved. EXCLUSIVE SHAFTS Copyright 011 ASK Limited all rights reserved. Copyright 011 ASK Limited all rights reserved. EXCLUSIVE

< B C8B816982C682D182E7816B90468E86816C8ADC82DE816A2E696E6464>

第 1 章 市の概況 1 2 3 4 46 11 3 40 55 7 7 1000 3 5 155ha 488ha 89ha 91ha 10ha 16ha 37ha 930ha ( 14ha ) (10ha 1 ) 44ha 6 第 2 章 公害苦情の概要 7 8 第 3 章 大気環境 9 10 11 12 13 14 NO 2 0.2ppm 0.1ppm 0.04ppm 06ppm 0.2ppm

L LM L B 12 c c L G L G L G L G L G L G bcb c L K J a B C 19 0de G c A f b b 123 G G 1 f 5 G G G G Gf d 09 d B 3 G f 3 G G G 1 2 1 2 G G G 1 G 1 G 2 3 1 2 G G G 1 G B B 1 2 3 4 5 6 7 8 9 G 2 2 B 12 f 4

20－121

20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150

arakidonsan.rtf

DHA (ARA) ARA DHA 50 DHA 20 DHA( ) γ 300 mg 170 mg 150 mg 78 mg 57 mg 3,200 mg 2,300 mg 1,700 mg 1,700 mg 1,700 mg β- E FAO DHA( ARA) DHA 2ARA 1 DHA 70mg 100g 35mg 100g 6 6 63 EPA DHA 63 6 EHA DHA 50 WEB

簡易入力システム（よくある質問集）

1 1. 4 2. 5 3. 6 3.1.... 6 3.2.... 8 3.3.... 10 3.4.... 12 4. 13 5. 20 6. 21 7. 22 23 1.... 24 2.... 38 3.... 39 4.... 58 5.... 59 61 1.... 61 1.1.... 61... 61... 63... 64 2... 65 2... 66 2... 67... 68...

#A A A F, F d F P + F P = d P F, F y P F F x A.1 ( α, 0), (α, 0) α > 0) (x, y) (x + α) 2 + y 2, (x α) 2 + y 2 d (x + α)2 + y 2 + (x α) 2 + y 2 =

#A A A. F, F d F P + F P = d P F, F P F F A. α, 0, α, 0 α > 0, + α +, α + d + α + + α + = d d F, F 0 < α < d + α + = d α + + α + = d d α + + α + d α + = d 4 4d α + = d 4 8d + 6 http://mth.cs.kitmi-it.c.jp/

‚å™J‚å−w“LŁñ›Ä

2007 172 FFFFFFFFF FFFFFFFFF 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 c d e cc bd b fb ag ag ed ed ed bd b b ef bf f df bd f bff d D f F d f 19 bd 20 21 F C e e f b b b 22 d d e f e f bf bd 23 24 222222222222222222222222222222222222222222222222222222222222222222222222

IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF

200823 877122 IF19989 HYDROPHILIC OINTMENT 1g 250mg 200mg 120mg 60 40mg 10mg 1mg 1mg HydrophilicOintment 200821 19518 19977 IF20082 IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug

,

23 1948 23 10 20 23 11 6 10 10 214 11 11 4 6,000 6,000 215 24 1949 18 69 1 2 24 31 34 24 10 11 12 14 15 2 2226 83, 24 1949 25 195017 26 1951 10 12 28 1953 22 25 1 20 31 10 15 10 1631 10 11 12 13 14 13

Taro-2複製

40 10 1 7 35 EF70 10 61 F - 1 116 7 123 61 EF70 9 1 2 1 10 1 49 50 49 50 99 5 100 4 1000 1000 2000 5000 4000 6000 9000 5 M D 6 601 602 501 502 2 3 40 10 K K 9 510 1 43 10 3.15 2.23 3.00 2.55 2.00 2.50

( ), ( ),,,,,

( ) ( ), ( ),,,,, ( ). ( ), ( ) ( ) ( ) ( ).. %. %.. %... %.. % ( ) ( ) , ( ) ( ). ( )...,.,.....,. ( ) ( ) ( ) ( ) ( ) B A / C ( ) ( ) ( ) ( ) B A,,,, ( ) ( )......... kg. kg =. kg. =. kg kg... kg....

: : 2001227 : 2

: : 2001227 : 2 mg/100gmg/100g mg/100g 3 10/102006 12/05 2/19, 2007 Zn 63 98 4 10% 5 Ramesh et al. 2004 6 Connoly et al. 2002 A IRT 7 8 2.11mg/100g143%56% 9 10 Alaria praelonga 11 2 12 13 14 15 16 1 1